TD Cowen analyst Joseph Thome reiterated a Buy rating on Rapport Therapeutics (NASDAQ: RAPP).The analyst commented: "RAP-219 Strongly Exceeds Expectations ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE